Journal article

Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies

Michelle T Fodero-Tavoletti, Shozo Furumoto, Leanne Taylor, Catriona A McLean, Rachel S Mulligan, Ian Birchall, Ryuichi Harada, Colin L Masters, Kazuhiko Yanai, Yukitsuka Kudo, Christopher C Rowe, Nobuyuki Okamura, Victor L Villemagne



INTRODUCTION: The introduction of tau imaging agents such as (18)F-THK523 offers new hope for the in vivo assessment of tau deposition in tauopathies such as Alzheimer's disease (AD), where preliminary (18)F-THK523-PET studies have demonstrated significantly higher cortical retention of (18)F-THK523 in AD compared to age-matched healthy individuals. In addition to AD, tau imaging with PET may also be of value in assessing non-AD tauopathies, such as corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) and Pick's disease (PiD). METHODS: To further investigate the ability of THK523 to recognize tau lesions, we undertook immunohistochemical and fluorescence studies in serial br..

View full abstract


Awarded by Alzheimer's Drug Discovery Foundation

Awarded by NHMRC

Awarded by Grants-in-Aid for Scientific Research

Funding Acknowledgements

We thank Fairlie Hinton and Geoff Pavey from the Victorian Brain Bank Network (VBBN) for sourcing and preparing the human brain tissue (HREC University of Melbourne 9414748). The VBBN is supported by The Florey Institute of Neuroscience and Mental Health, The Alfred and the Victorian Forensic Institute of Medicine, and it is funded by Australia's National Health & Medical Research Council (NHMRC) and Parkinson's Victoria. The research was supported in part by Alzheimer's Drug Discovery Foundation Research Grant 20101208 AFTD and NHMRC project grant 1044361.